Together, our findings highlight a previously underappreciated prognostic factor, i.e., EIF4EBP1/4EBP1, which may help refining risk stratification of NB patients, including MYCN-non-amplified, stage 4 and high-risk patients, and could potentially assist in tailoring more personalized treatment options. The gene discussed is MYCN; the disease is neuroblastoma.